Angina Pectoris Clinical Trial
Official title:
Effectiveness of External Counter Pulsation (ECP) Therapy in Stable Angina Pectoris Patients; a Proof of Principal Clinical Trial
External Counterpulsation (ECP) is a non-invasive therapy using pressured cuff that is performed on patients with refractory stable angina pectoris to relieve symptoms and increase quality of life. In Indonesia, waiting time for getting coronary artery bypass grafting (CABG) procedure for revascularization treatment in stable angina pectoris patients is way longer than international recommendation which correlates with increase morbidity and mortality during the waiting time. Utilization of ECP for such patients who wait for CABG procedure is still unclear. The investigator aim to evaluate efficacy of addition of ECP compared with medical therapy alone for this population. The efficacy is evaluated using measurement from echocardiography result, treadmill test result, and clinical outcome. if applicable, examination of myocardial perfusion using nuclear examination will also be performed.
Waiting time for elective CABG procedure in Indonesia is usually longer than six weeks, way longer than the European society of cardiology recommendation. During the waiting time, patients still complain of having troubling chest pain and at risk from 1.7% mortality even after optimal medical therapy. ECP is a non-invasive therapy using a pressured cuff performed on patients that have been utilized in refractory angina pectoris patients to relieve symptoms, increase the quality of life, and decrease future major adverse cardiac events (MACE). This study is proof of principal clinical trial to evaluate the efficacy of addition ECP therapy after optimal medical therapy for stable angina pectoris patients waiting for CABG in Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Eligible patients will be informed about the study and randomized to the intervention arm. Patients in the experimental arm will undergo ECP therapy consisting of 36 sessions, each session @1 hour/day, five days a week with an initial pressure of 300mmHg. No intervention will be given to patients in the control arm. The primary and secondary endpoint is the change in variables measured before and after the intervention is fully implemented. The primary endpoint variables are global longitudinal strain (GLS), Left ventricular ejection fraction (LVEF), Time to ST-Segment depression, duration of treadmill test, the Canadian cardiovascular society (CCS) score, and the Seattle angina questionnaire (SAQ) score. The secondary endpoint variable will be myocardial perfusion score measured as Summed Rest Score, Summed Stress Score, Summed Difference Score, Myocardial Micro-alternation Index (MMI), the level of Vascular Endothelial Growth Factor (VEGF), microRNA-92a (miR-92a), NT pro BNP, Troponin, incidence of MACE, general quality of life based on questionnaire The Indonesian EQ-5D-5L, and effectiveness of ECP for stable angina pectoris patients with pharmaco-economy studies. This change will then be compared between the intervention experimental arm and control arm. Safety oversight by a Data and Safety Monitoring Board (DSMB) will be conducted by independent parties. Internal Data Monitoring Committee (DMC) will be established to oversee the study, focused on data quality. Quality control (QC) procedures will be implemented beginning with the data entry system. Data QC checks that will be run on the database will be automatically generated weekly, and any quality issues identified will be reviewed by the DMC a plan put in place for resolution. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Recruiting |
NCT02773615 -
CT Perfusion Added to CT Angiography
|
||
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Terminated |
NCT02548611 -
Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
|
Phase 4 | |
Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01425359 -
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
|
Phase 4 | |
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
Completed |
NCT01604486 -
Natural Ischaemic Preconditioning Before First Myocardial Infarction
|
N/A | |
Completed |
NCT00811772 -
Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis
|
N/A | |
Completed |
NCT00131183 -
Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina
|
Phase 4 | |
Completed |
NCT00184444 -
Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients
|
N/A | |
Completed |
NCT00235404 -
Randomized Controlled Trial of Health Care to Elderly Patients.
|
N/A | |
Terminated |
NCT00157742 -
Comparison of SCS and PMR in Patients With Refractory Angina Pectoris
|
Phase 4 | |
Completed |
NCT00000510 -
Platelet-Inhibitor Drug Trial in Coronary Angioplasty
|
Phase 3 | |
Completed |
NCT00005148 -
Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships
|
N/A | |
Not yet recruiting |
NCT03657758 -
Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]
|
Phase 4 | |
Completed |
NCT05050773 -
Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)
|
||
Completed |
NCT00093223 -
A Safety Study of ABI-007 for In-Stent Restenosis
|
Phase 2 | |
Active, not recruiting |
NCT02508714 -
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
|
N/A |